Luis A. Jiménez-López, Dirección de Educación e Investigación en Salud, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social, Veracruz, México
Jorge L. Hernández-Azuara, Servicio de Urología, Unidad Médica de Alta especialidad No. 14 Adolfo Ruiz Cortines, Veracruz, Veracruz, México
Jose M. Reyes-Ruiz, Departamento de Educación e Investigación. Unidad Médica de Alta especialidad No. 14 Adolfo Ruiz Cortines, Veracruz, Veracruz, México
Juan P. Santos-Uscanga, Departamento de Educación e Investigación, Unidad Médica de Alta especialidad No. 14 Adolfo Ruiz Cortines, Veracruz, Veracruz, México
Introduction: The immunoinflammatory indices IIS and HALP have been used to predict the prognosis of various neoplasms and acute inflammatory processes. Can they differentiate prostate cancer from an acute inflammatory process such as prostatitis? Objective: To evaluate the usefulness of IIS and HALP score in the detection of prostate cancer in patients with PSA ≤ 10 ng/dL. Method: Retrospective study including prostate biopsied patients in search of cancer from December 2022 to May 2023. ROC curves were performed to calculate the area under the curve (AUC), sensitivity and specificity. Results: 25 patients had prostatitis and 25 had prostate cancer. The age range was 55 to 81 years. The median IIS was 612.85, while HALP score had a median of 47.59. The AUC of IIS was 0.616, with sensitivity of 76% and specificity of 52%. The AUC of HALP score was 0.13 with a sensitivity of 88% and specificity of 28%. Conclusions: IIS and HALP score had no efficacy in differentiating prostatitis from prostate cancer. However, prospective studies with a larger number of patients are required to validate the results.
Keywords: Prostate cancer. Systemic immune - inflammation index. HALP.